Updated Jul 16, 2026
Hahn Mark W has filed 1 SEC Form 4 filing across 1 company in the last 90 days — selling. Lifetime open-market sales: $11.26M.
Mark W. Hahn is the Chief Financial Officer at Soleno Therapeutics Inc, a biopharmaceutical company focused on developing treatments for rare diseases. He has also held a similar role at Verona Pharma plc.
| Role | Insider |
|---|---|
| Notability | 30/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-18 | SLNO | SOLENO THERAPEUTICS INC | D — Derivative transaction | 10.0K | — | |
| 2025-10-13 | SLNO | SOLENO THERAPEUTICS INC | A — Grant or award | 10.0K | $0.00 | |
| 2025-10-07 | VRNA | Verona Pharma plc | D — Derivative transaction | 3.29M | — | |
| 2025-10-07 | VRNA | Verona Pharma plc | M — Option exercise | 3.29M | — | |
| 2025-10-07 | VRNA | Verona Pharma plc | D — Derivative transaction | 11.26M | — | |
| 2025-08-29 | VRNA | Verona Pharma plc | G — Bona-fide gift | 1.20M | $0.00 | |
| 2025-08-01 | VRNA | Verona Pharma plc | S — Open-market sale | 208.9K | $13.14 | $2.75M |
| 2025-08-01 | VRNA | Verona Pharma plc | M — Option exercise | 255.7K | $0.00 | |
| 2025-07-07 | VRNA | Verona Pharma plc | F — Tax withholding / forfeiture | 90.3K | $11.44 | $1.03M |
| 2025-07-07 | VRNA | Verona Pharma plc | M — Option exercise | 229.5K | $0.00 | |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 183.7K | $5.01 | $920K |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 640.0K | $5.01 | $3.20M |
| 2024-12-06 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 58.2K | $5.00 | $291K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 1.6K | $5.00 | $8K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 98.7K | $5.01 | $494K |
| 2024-12-02 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 12.9K | $5.00 | $65K |
| 2024-11-26 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 800 | $5.00 | $4K |
| 2024-11-26 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 1.6K | $5.00 | $8K |
| 2024-11-13 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 2.4K | $5.00 | $12K |
| 2024-11-05 | VRNA | Verona Pharma plc | S — Open-market sale [10b5-1] | 80.8K | $4.39 | $354K |
Mark W. Hahn is the Chief Financial Officer at Soleno Therapeutics Inc, a biopharmaceutical company focused on developing treatments for rare diseases. He has also held a similar role at Verona Pharma plc.…
1 primary Form 4 filings in the last 90 days, covering 1 company.
Recorded transactions: 0 open-market purchases () and 17 open-market sales ($11.26M) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Hahn Mark W profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.